Abbott Laboratories (NYSE:ABT) Stock Sold Rep. Julie Johnson

Representative Julie Johnson (Democratic-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on May 12th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 5/12/2026.

Abbott Laboratories Trading Up 3.2%

Shares of ABT traded up $2.92 during trading hours on Thursday, reaching $93.41. 7,062,411 shares of the company traded hands, compared to its average volume of 12,165,914. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.54. The company’s fifty day moving average price is $89.39 and its two-hundred day moving average price is $105.69. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $162.71 billion, a price-to-earnings ratio of 26.16, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. Abbott Laboratories’s payout ratio is 70.59%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a new global licensing agreement with ALZpath to develop a blood-based Alzheimer’s diagnostic test for its Alinity ci-series systems, a potential long-term growth opportunity in a high-profile, fast-growing testing category. ALZpath signs licensing deal with Abbott to develop Alzheimer’s blood test
• Positive Sentiment: Wall Street sentiment remains constructive, with reports highlighting bullish hedge-fund positioning, analyst-implied upside, and a Strong Buy view from some market sources, which can support the shares. How Does Wall Street View Abbott Laboratories (ABT)’s Outlook?
• Positive Sentiment: Additional articles this week emphasized Abbott’s durable business model, dividend streak, and emerging-markets momentum, reinforcing the view that ABT is a defensive, cash-generative healthcare name. Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy
• Neutral Sentiment: Abbott also said it will host its second-quarter 2026 earnings conference call on July 16, keeping investors focused on upcoming results but not changing fundamentals today. Abbott hosts conference call for second-quarter earnings
• Negative Sentiment: A Missouri appeals court did not advance Abbott’s appeal of a $495 million preterm baby formula verdict, leaving a large legal overhang in place and potentially limiting upside. Missouri appeals court won’t send Abbott’s appeal of $495 million preterm baby formula verdict to higher court

Analyst Ratings Changes

Several research firms have recently issued reports on ABT. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a report on Wednesday, April 22nd. Piper Sandler restated an “overweight” rating and issued a $115.00 target price on shares of Abbott Laboratories in a report on Monday. Bank of America reduced their price objective on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Jefferies Financial Group reduced their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Benchmark cut their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $118.30.

Insider Activity

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories in the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories in the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter worth $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories during the fourth quarter valued at $26,000. Institutional investors own 75.18% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.